South Africa grapples with HIV funding crisis after US aid cutoff
South Africa's Health Minister, Aaron Motsoaledi, has dismissed media reports claiming the country's HIV response is in crisis, despite the government's struggle to secure new funding, following US aid cuts.
South Africa's Health Minister refuted claims that the nation's HIV response is in a crisis despite recent financial difficulties.
The U.S. government significantly reduced its PEPFAR funding, previously contributing 17% to South Africa's HIV budget.
Health professionals and activists warn of rising challenges and demand immediate governmental solutions to the crisis.
Until recently, the U.S. PEPFAR initiative covered approximately 17% of South Africa's HIV budget. However, funding was significantly reduced after the Trump administration cut support to USAID, the world's largest donor organization focused on health and humanitarian aid.
South Africa further strained relations with the U.S. after enacting the Expropriation Without Compensation Act—a policy impacting land ownership among white Afrikaners—which contributed to a substantial funding gap.
South Africa's HIV crisis
According to Reuters, HIV viral load testing in South Africa has declined drastically due to funding shortages. Medical professionals describe the situation as a worrying sign of strain on the healthcare system.
While Minister Motsoaledi acknowledged disruptions, he denied claims of a systemic breakdown, attributing the narrative to media misinformation.
'If the tests have gone down... we will try to correct it, but we do not think it is a train smash,' he told reporters.
Reuters also reported that 8,000 healthcare workers have lost their jobs after US funding ended, despite previously supporting 15,000 workers' salaries. The health minister admitted there's no clear plan in place for these workers.
'I'm not going to stand here in front of you and claim that we have got any plan for the 8,000 people beyond just speaking to funders and our own Treasury, which still have not yet responded on what's going to happen, ' he said.
His remarks sparked nationwide criticism, particularly from health sector professionals who accused the government of inadequately addressing the funding shortfall, warning that the impact is already being felt.
In response, HIV activists disrupted a parliamentary session in Cape Town, demanding immediate action. Fatima Hassan, founder of the Health Justice Initiative, stated, " The health minister is in denial, and once again, South Africa will have to deal with the harmful public health consequences of not just the Trump administration, but also our own government's failure to plan adequately for months '
Recall that President Trump had previously expressed concerns about the hateful rhetoric and government policies fueling violence against certain white landowners in South Africa. The shutdown of HIV aid was reportedly part of a broader effort to address the alleged mistreatment of Afrikaners.
South Africa, once at the epicenter of the global HIV/AIDS epidemic, has made substantial progress in reducing infections and deaths over the past two decades.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 minutes ago
- Yahoo
HIV/AIDS: Facts about the viral infection that attacks the immune system
When you buy through links on our articles, Future and its syndication partners may earn a commission. QUICK FACTS ABOUT HIV What it is: A lifelong viral infection that weakens the immune system, if left untreated Prevention methods: Taking preventive medicines called PrEP, using condoms, and avoiding needle sharing Treatments: Medicines called antiretroviral therapy (ART) Human immunodeficiency virus (HIV) is a germ that causes a lifelong infection that slowly weakens the immune system. Though the infection is lifelong, medicines can keep the virus in check and help people reach lifespans of near-normal length. However, when people don't have access to those medicines, HIV infections progress to an advanced stage called acquired immunodeficiency syndrome (AIDS), which is fatal within about three years if not treated. When a person has AIDS, most of their key, disease-fighting immune cells are lost. This loss of immune protection leaves the person vulnerable to deadly infections and cancers. Although an HIV diagnosis was once a death sentence, scientists have developed treatments that suppress the virus and enable people to live long lives without transmitting the disease to others. Additionally, there are now effective preventive medications that can dramatically reduce the risk of getting HIV in the first place. There is not yet a widespread cure for HIV/AIDS, although a handful of people have been cured of the infection or are in long-term remission thanks to special stem-cell transplants, specially cell transplants from people who have genes that make them resistant to the virus. Scientists are exploring potential avenues for a cure, which could someday mean that people who contract HIV could be rid of the infection rather than having to take medication for life to manage the disease. HIV/AIDS remains a major public health threat worldwide, with an estimated 39.9 million people living with the disease at the end of 2023. Around 630,000 people died from illnesses related to AIDS the same year; by weakening the immune system, AIDS opens the door to these fatal diseases. HIV can spread through contact with an infected person's bodily fluids, although it's important to note that not all bodily fluids can transmit the virus. Bodily fluids that can spread HIV include blood, semen, preseminal fluid, vaginal secretions, breastmilk and rectal discharge (liquid from the anus that's not blood or stool). HIV is not transmitted through saliva, sweat or tears. It's also not spread through the air or through casual contact, such as hugging, shaking hands or sharing food. For transmission to occur, the bodily fluids containing HIV must come into contact with mucous membranes — tissues that line cavities in the body, like the vagina, anus or mouth. The fluids can also transmit HIV when they come into contact with cuts or sores, or when they're introduced to the bloodstream via contaminated needles, for instance. Most people who contract HIV get it through unprotected anal or vaginal sex — meaning sex without a condom or without HIV-preventing medications. People can also contract the virus by sharing the equipment used to inject drugs, such as needles or syringes. Babies can get HIV in the womb, during childbirth or from breastfeeding, if their mother has HIV. People living with HIV who take medicines called ART can suppress the virus to the point that it can't spread via sex. These "virally suppressed" people also have a much lower chance of transmitting HIV to their kids via pregnancy, childbirth or breastfeeding. They are also less likely to spread the virus via shared injection equipment, although experts aren't sure exactly how much the risk is reduced. The symptoms of HIV vary depending on how far the disease has progressed. The virus can spread from one person to another at any stage of the infection, unless the infected person is taking ART and has reached "viral suppression" (see glossary). The initial stage is called "acute HIV infection." Within two to four weeks of contracting the virus, many people develop a flu-like illness involving symptoms like fever, headache, rash and sore throat. These symptoms can last from a few days to a few weeks. Some people have no symptoms at this stage, however. The viral load, or amount of HIV in the blood, at this stage is very high. The second stage of the disease is "chronic HIV infection," during which the virus continues to multiply but at a slower speed than during acute infection. This stage is also called "clinical latency" or "asymptomatic HIV infection," as many people don't feel sick during it. People can remain in this stage of the disease for 10 to 15 years, though some pass through it more quickly. As the virus multiplies, levels of an important type of immune cell — CD4 T lymphocytes — decline. Without treatment, the disease will eventually enter its most advanced stage: AIDS. This can come with a wide range of symptoms, including rapid weight loss; recurring fever; night sweats; extreme tiredness; prolonged swelling of the lymph nodes; diarrhea; sores of the mouth, anus or genitals; and blotches on or under the skin or inside the mouth, nose or eyelids. It can also trigger neurological problems, like memory loss. AIDS raises the risk of severe bacterial infections and cancers, including lymphomas and Kaposi's sarcoma. It can also worsen viral infections, such as hepatitis B and mpox. Without any treatment, people with AIDS typically survive about three years. HIV and AIDS are related, in that AIDS is the most advanced stage of an HIV infection, and therefore, the HIV virus causes both conditions. AIDS can also be called a "stage 3 HIV infection." AIDS is defined in part by a very low CD4 count of fewer than 200 CD4 cells per cubic millimeter (mm3) of blood. Generally speaking, the CD4 counts of healthy teens and adults are around 500 to 1,200 cells/mm3. Anything below 500 cells/mm3 is considered low, and 200 cells/mm3 marks the threshold for an AIDS diagnosis. Doctors also diagnose AIDS by considering a patient's history of "AIDS-defining illnesses." These are medical conditions often seen in people with AIDS because their immune systems can't fight the illnesses off. They include "opportunistic" infections — those caused by germs that wouldn't necessarily harm a person with a well-functioning immune system. Such infections include a fungal infection called extrapulmonary cryptococcosis, recurrent blood infections with Salmonella bacteria, the parasitic infection toxoplasmosis, and lower respiratory infections caused by the herpes simplex virus. The bacterial disease tuberculosis poses a major risk to people with AIDS, and it is currently the leading cause of death for people living with HIV/AIDS worldwide. AIDS-defining illnesses also include cancers such as Kaposi's sarcoma, Burkitt's lymphoma and invasive cervical cancer. Others include HIV encephalopathy, which affects brain function, and HIV wasting syndrome, which causes extreme weight loss and weakness. Complications of AIDS-defining illnesses raise the risk of death, but the degree of risk varies among diseases. At all three stages of the infection, HIV is treated with antiretroviral therapy (ART) — combinations of medications that drive down the amount of HIV in the blood. Different ART drugs work in different ways to keep the amount of virus, or viral load, in check. They are available as daily pills or as shots given periodically throughout the year, depending on the person's treatment plan. It's key for patients to take their medication as prescribed, because missing pills or shots can open the door for the virus to multiply, as well as develop drug resistance, which causes the medication to work less well. ART medications can also interact with other drugs and carry some risk of serious side effects, so patients work with their medical providers to figure out which drug combination is best for them. The goal of ART is "viral suppression," which describes when a person's viral load falls low enough that there are 200 or fewer copies of the virus's genetic material per milliliter (mL) of blood. Historically, tests weren't sensitive enough to detect levels of HIV below that threshold, so doctors called this level "undetectable." Studies also found that people who reach viral suppression can't transmit the virus via sex; have a lower chance of spreading the virus through pregnancy, childbirth or breastfeeding; and likely have a lower chance of spreading it through needle sharing. This is why the slogan "undetectable equals untransmittable," or "U = U," was coined. Nowadays, some tests for HIV are extremely sensitive, so they can detect viral loads significantly below 200 copies/mL. However, experts emphasize that 200 copies/mL is still the critical threshold at which transmission risk becomes extremely low. If a person with HIV/AIDS develops another medical condition, such as an AIDS-defining illness, the individual would receive treatment for that condition in addition to their ART regimen. There is no widespread cure for HIV/AIDS. However, a handful of people have been cured of their HIV infections through stem cell transplants, and a few more are considered "potentially" cured via the same process. Stem cells can develop into different types of cells in the body. In certain cancers that affect blood cells, stem cell transplants can be used to replace the cells lost in the course of cancer treatments such as chemotherapy. Each individual who has been cured of HIV also had one of these cancers, so their doctors searched for stem cell donors who carry a rare gene that makes them resistant to HIV infection. By swapping in cells from an HIV-resistant individual, the procedure essentially locks the virus out of the patient's CD4 cells. There is one exception to this rule: A person known as the "Geneva patient" was potentially cured of HIV after a stem cell transplant, but the donor didn't have this special genetic resistance. It's unclear exactly why the man entered long-term remission from the infection after this procedure, but scientists are investigating. There have also been a couple of cases in which people's own immune systems somehow rallied against the virus and controlled it without treatment; these people are known as "elite controllers." Scientists hope to learn from both the stem cell recipients and from elite controllers to discover cures that could reach far more people with HIV/AIDS. Meanwhile, some researchers are exploring the use of gene-editing tools like CRISPR to cure the infection, while others are investigating the use of drugs and modified immune cells. Antiretroviral therapy (ART) – Combinations of medications that lower the amount of HIV in a person's blood. These drugs, given as pills or shots, prevent the viral infection from progressing to AIDS and dramatically lower a person's risk of complications and of transmitting the virus to others. Pre-exposure prophylaxis (PrEP) – Medicines that people at risk of being exposed to HIV take to prevent the infection. Viral load – The amount of HIV in a person's blood. This is measured in terms of the number of HIV RNA molecules — the virus's genetic material — found in a milliliter of blood. It's an important way to measure how well ART is working. Viral suppression – When a person's viral load falls to 200 copies/mL or lower. Viral suppression is the goal of ART, as it both lowers a person's likelihood of spreading the virus and extends their lifespan by preventing the infection from progressing to AIDS. CD4 T lymphocyte – A type of white blood cell that helps coordinate the actions of other immune cells to fight infections. HIV infects CD4 cells and uses them to multiply while the virus depletes the number of CD4 cells in the body. Image 1 of 4 In the 1980s and 1990s, groups organized "die-ins" to protest the lack of U.S. government attention to the ongoing HIV/AIDS crisis. Die-ins were also conducted to push for support for research to uncover effective treatments and, once treatments were discovered, to demand that those drugs be released to the public. The AIDS Coalition to Unleash Power — known as ACT UP — was a major force behind such protests and remains an active organization today. Image 2 of 4 Kaposi's sarcoma, an example of an AIDS-defining illness, characteristically causes big, purple patches or nodules to appear on the skin and mucous membranes. Image 3 of 4 The public health slogan "U = U," depicted on this sign, refers to the fact that people living with HIV who have undetectable viral loads cannot transmit the virus to others via sex. It stands for "undetectable = untransmittable." Image 4 of 4 The "Berlin patient," pictured here, was the first person cured of HIV via a stem cell transplant. His name was later revealed to be Timothy Ray Brown. Brown went on to launch a foundation under his name that was dedicated to fighting HIV/AIDS. We could end the AIDS epidemic in less than a decade. Here's how. In a 1st, HIV vaccine triggers rare and elusive antibodies in humans Nearly 3 million extra deaths by 2030 could result from HIV funding cuts, study suggests
Business Insider
3 hours ago
- Business Insider
U.S. aid cuts leave $11 million in birth control supplies for Sub-Saharan Africa stranded
Millions of contraceptives intended to support women across Africa are reportedly sitting idle in warehouses and are at risk of being destroyed due to delays and funding cuts from the United States government. Millions of contraceptives intended for Africa are at risk of expiration due to U.S. government delays and funding cuts. The supplies, valued at $11 million, include various contraceptive tools meant for low-income countries. The delayed distribution may lead to increased health risks and strain on the healthcare systems in Africa. A former US official and aid worker revealed that the contraceptives, valued at around $11 million, include condoms, birth control pills, implants, and intrauterine devices (IUDs), which were originally intended to help women in low-income countries, particularly in sub-Saharan Africa, avoid unplanned pregnancies and protect themselves from sexually transmitted infections like HIV. However, the supplies are now stuck in storage facilities in Belgium and Dubai. According to sources at Reuters, the U.S. The Agency for International Development (USAID) has decided not to pay for their delivery and is no longer donating them as part of foreign aid programs. This delay stems from policy changes implemented by the former U.S. President Donald Trump, who reduced foreign assistance under his 'America First' approach: USAID gives update A recent internal memo from USAID, dated April, highlighted the urgent need to transfer the stock to prevent waste and minimize further costs. Despite this warning, a concrete plan has yet to be announced. With each passing month, the contraceptives edge closer to expiration. A senior U.S. State Department officials further confirmed that the contraceptives remain in storage, but no final decision has been made regarding their fate. The situation, according to the US official, is both frustrating and urgent for many health workers and aid groups. Another former USAID official said the stalled shipment represents nearly 20% of all contraceptives the U.S. usually donates each year, adding that if no solution is found soon, the entire stock could be destroyed, at a cost of hundreds of thousands of dollars. 'These supplies were meant to help women who have little or no access to family planning—girls fleeing conflict, mothers in refugee camps, and young women at risk of early pregnancy, ' one source said. ' The condoms in the shipment were also meant to help prevent the spread of HIV, which continues to impact millions across the region.' It added. Karen Hong, head of supply chain at the United Nations Population Fund (UNFPA), said her team is already working on an alternative plan. ' We cannot dwell on an issue for too long; when urgency and clarity don't align, we have to move on,' she said.
Yahoo
5 hours ago
- Yahoo
Better Buy: Palantir Stock vs. UnitedHealth Group Stock
Excitement around Palantir seems to rise by the day thanks to the company's ongoing artificial intelligence (AI) tailwinds. UnitedHealth Group has experienced a flurry of operational challenges this year, and investors have punished the stock. While Palantir's momentum looks tempting and UnitedHealth's scandals may spook investors away, valuation trends between these two stocks show a compelling case as to which is the better buy right now. 10 stocks we like better than Palantir Technologies › Two stocks that have been at the center of financial news stories throughout the year are data mining specialist Palantir Technologies (NASDAQ: PLTR) and health insurance giant UnitedHealth Group (NYSE: UNH). The reasons these two companies are fetching so much attention, however, couldn't be more opposite. Palantir has emerged as a darling of the artificial intelligence (AI) revolution. As of this writing (June 5), shares of the stock have gained nearly 60% on the year -- making it one of the top performers in the S&P 500 and Nasdaq-100 indexes. By contrast, UnitedHealth Group stock is the worst-performing name in the Dow Jones Industrial Average -- with shares plummeting by more than 40%. Is now the time to hop on the Palantir train, or should investors take an inventory check on UnitedHealth and choose to buy the dip? It's been just over two years since Palantir released its Artificial Intelligence Platform (AIP), a software suite that's proven to be a transformative game changer in the company's pursuit of competing with the largest players in the tech landscape. Since releasing AIP, Palantir has unlocked a new wave of revenue acceleration -- thanks in large part to the company's impressive penetration of the private sector. For most of its history, Palantir relied heavily on government contracts from the Department of Defense (DOD). While deals with the U.S. Military and its allies are still an important cornerstone of Palantir's business, AIP has helped the company break ground in a host of other use cases -- financial fraud, supply chain and logistics, aviation, and much more. What might be most impressive about Palantir's transformation over the last two years is how rapidly the company transitioned from a cash-burning operation to one that generates consistent profitability. Not only is Palantir acquiring new business, but it's also monetizing these customers in a profitable way. That's a lucrative combination, indeed. The one idea that's paramount for smart investors to understand is that while Palantir's business is soaring, so is the company's share price. As of this writing, Palantir trades at a price-to-sales (P/S) ratio of 97. Not only is that magnitudes higher than any of its peers in the software realm, but it is historically high compared to what investors witnessed during the dot-com bubble in the late 1990s. I don't think I'm the only one who has noticed the pronounced valuation expansion in Palantir, either. Consider that Cathie Wood's Ark Invest portfolio has been trimming Palantir stock as of late, and billionaire money manager Stanley Druckenmiller completely dumped his firm's stake in the AI stock during the first quarter. UnitedHealth Group's coverage couldn't be any more different than Palantir's. While investors continue to cheer on Palantir's dominance, it seems that only negativity surrounds UnitedHealth at the moment. At the core of the health insurer's problems are some operational hiccups. Mismanagement in forecasting utilization rates in the company's Medicare Advantage business, as well as some unforeseen challenges in the pharmacy benefits management (PBM) segment, caused management to reduce financial guidance for 2025. If this weren't enough to get investors worked up, UnitedHealth also replaced its CEO as the company seeks to right the ship and turn things around by next year. UnitedHealth's downward revision and executive changes were met with a stock sell-off for the ages. Don't believe me? As of this writing, shares of UnitedHealth trade at $296 -- hovering near a five-year low. Despite its near-term headwinds, UnitedHealth stock looks awfully tempting at a forward price-to-earnings (P/E) multiple of just 13. When you consider that insiders have been buying the stock in the aftermath of this epic sell-off, I'm cautiously optimistic that all of the bad news surrounding UnitedHealth is priced in. On the other side of the equation, I think it's becoming increasingly difficult to argue that max upside isn't already priced into Palantir. Sure, I'm bullish on the company's future, but buying the stock near an all-time high doesn't seem like a prudent idea right now. Overall, I'd choose to buy the dip in UnitedHealth as opposed to chasing the momentum fueling Palantir stock at the moment. Before you buy stock in Palantir Technologies, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Palantir Technologies wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $669,517!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $868,615!* Now, it's worth noting Stock Advisor's total average return is 792% — a market-crushing outperformance compared to 173% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Adam Spatacco has positions in Palantir Technologies. The Motley Fool has positions in and recommends Palantir Technologies. The Motley Fool recommends UnitedHealth Group. The Motley Fool has a disclosure policy. Better Buy: Palantir Stock vs. UnitedHealth Group Stock was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
